Great question @jen_antibody
Assuming that the email template was submitted to meet the restrictions outlined in the second paragraph under “Dissemination” above, you would not be required to resubmit the template. Yes, you should provide the “attachment name” within it’s submission and convey that the intent is to disseminate through the approved template (efile #).
No, you are not required to resubmit the template due to updates to pieces which were previously listed through the template.
Let us know if you have any further questions.

Do you have questions about particular sections of the PAAB code? Do you have insights on how sections of the code be improved? Do you want to share insights about how related standards are addressed in other jurisdictions? Post here.

15Topics

16Posts

Hey @AnetteCPC
This would not be acceptable as the cookies would be placed on the computer, but they would not be able verify who is using that computer. If an HCP was to sign into a verified site on a shared computer, sign out and leave that computer, the next user would be exposed to advertising without verification that they are an HCP. This would contravene consumer regulations.

You are correct in your assumption that this would brand the email and its content. When we link branded and unbranded, everything becomes branded. As the sign-off is content within the entirety of the message, the disease content becomes branded and needs to be reviewed in this context. Note that this would also trigger code section 2.10.1 and 2.4, requiring the inclusion of the indication and fair balance.